HEMOSTEMIX INC chart

Last update: 2021-02-12
Key statistics and financials
Revenue per share N/A
Dividend & YieldN/AC$ (N/A)
Beta 0.15
Market capitalization 22.36M
Operating cash flow -3.48M
ESG Scores unknown

Company description

Hemostemix Inc., a biotechnology company, develops, manufactures, and commercializes blood-derived stem cell therapies for medical conditions. The company develops cell therapy products from the patient's own blood, which is a non-invasive source of therapeutic cells. Its lead product is ACP-01, an autologous cell therapy, which is in Phase II clinical trial for the treatment of critical limb ischemia in Canada and the United States, as well as for the treatment of heart and peripheral arterial diseases. The company is also developing various types of cell products, such as synergetic cell populations and neural cell precursors. Hemostemix Inc. is headquartered in Calgary, Canada.

Sector: Healthcare - Industry: Biotechnology

Financial data

Diluted earning per share

Net income vs Operating income

Asset vs Liabilities

Financial Statements

Cashflow Statement 2018-12-31 2019-12-31 2020-12-31 2021-12-31
Change To Liabilities 709.66k 910.68k 1.16M
Total Cashflows From Investing Activities -6.14k -6.14k
Net Borrowings 1.96M 1.96M -1.85M
Total Cash From Financing Activities 201.65k 1.96M 6.21M
Change To Operating Activities 1.18M 40.53k -1.96M
Issuance Of Stock 201.65k 8.77M 8.77M
Net Income -6.19M -4.87M -7.77M
Change In Cash -2.49M -1.45M 233.89k
Effect Of Exchange Rate
Total Cash From Operating Activities -2.69M -3.4M -5.98M
Depreciation 1.69k 1.69k 2.45k
Change To Account Receivables -26.2k 74.92k -32.2k
Other Cashflows From Financing Activities -706.86k -706.86k -706.86k
Change To Netincome 1.64M 438.23k 2.62M
Capital Expenditures -6.14k -6.14k

Income Statement 2018-12-31 2019-12-31 2020-12-31 2021-12-31
Research Development 2.26M 2.35M 650.05k
Income Before Tax -6.18M -4.87M -7.77M
Net Income -6.19M -4.87M -7.77M
Selling General Administrative 2.52M 1.96M 1.9M
Gross Profit
Ebit -6.42M -4.64M -4.88M
Operating Income -6.42M -4.64M -4.88M
Interest Expense -104.98k -104.98k -113.03k -93.91k
Income Tax Expense
Total Revenue
Cost Of Revenue
Total Other Income ExpenseNet 241.64k -226.46k -2.89M
Net Income From Continuing Ops -6.18M -4.87M -7.77M
Net Income Applicable To Common Shares -6.19M -4.87M -7.77M

Balance Sheet Statement 2018-12-31 2019-12-31 2020-12-31 2021-12-31
Total Liabilities 1.17M 4.15M 3.42M
Total Stockholder Equity 487.8k -4.05M -1.1M
Other Current Liabilities 390.54k 1.04M 1.24M 1.04M
Total Assets 1.66M 104.28k 2.32M
Common Stock 31.03M 31.03M 37.89M
Other Current Assets
Retained Earnings -36.6M -41.47M -49.24M
Treasury Stock 3.14M 439.71k 1.54M
Cash 1.47M 24.06k 257.95k
Total Current Liabilities 1.17M 4.15M 3.42M
Other Stockholder Equity 3.14M 439.71k 1.54M
Property, Plant, and Equipment 4.45k 2k
Total Current Assets 1.66M 99.83k 2.32M
Net Tangible Assets 487.8k -4.05M -1.1M
Net Receivables 191.22k 75.77k 2.06M
Accounts Payable 783.91k 1.04M 1.98M 3.31M


Insider Transactions

Here are the insider transactions of stock shares related to HEMOSTEMIX INC:

Filer Name Transaction Text Ownership Date Filer Relation Shares
Smeenk, ThomasAcquisition or disposition in the public market at price 0.24 per share.D2022-05-04Director of Issuer20k
Smeenk, ThomasAcquisition or disposition in the public market at price 0.25 per share.D2022-04-18Director of Issuer300k
Lacey (Peter Alan)Compensation for services at price 0.15 per share.I2022-03-03Director of Issuer446.34k
Smeenk, ThomasAcquisition or disposition carried out privately at price 0.11 per share.D2022-02-28Director of Issuer700k
Smeenk, ThomasAcquisition or disposition in the public market at price 0.10 per share.D2021-12-03Director of Issuer5k
Smeenk, ThomasAcquisition or disposition in the public market at price 0.11 per share.D2021-12-03Director of Issuer5k
Smeenk, ThomasAcquisition or disposition in the public market at price 0.17 per share.D2021-08-03Director of Issuer20k
Lacey (Peter Alan)D2021-06-17Director of Issuer19.29M
Lacey (Peter Alan)Stock split or consolidation at price 0.16 per share.D2021-06-17Director of Issuer96.46k
Lacey (Peter Alan)Acquisition or disposition in the public market at price 0.21 per share.I2021-06-14Director of Issuer237k

Insider transaction explanations

Insider buying is the legal purchase of shares by a senior executive or director of a company. "Filer Name" corresponds to the name of the stock buyer or seller. "Transaction Text" describes the transaction. "Ownership" gives information about the transaction type. "Date" is the reported transaction date. "Filer Relation" gives the role of the insider in the company. "Shares" is the value of the transaction. You will find the complete description of the General Transaction Codes on the SEC dedicated page


Investment strategy backtesting

These are the result of three automatic investment systems applied to HEMOSTEMIX INC. You will find the performance of an systematic investment system, a momentum strategy, and a buy the dip trading strategy.


Systematic investment results on HEMOSTEMIX INC

Here is the result of two systematic investment strategies applied to HEMOSTEMIX INC. The first strategy automatically buys the first day of the month, and the second strategy buys the fifteenth day of the month.

Systematic investment equity curve on HEMOSTEMIX INC

The following chart shows the equity curve of the two systematic investment strategies applied to HEMOSTEMIX INC:

HEMOSTEMIX INC automated entries

The systematic investment strategy that buys the first day of the month would give a performance of 1670.83% on the backtest period.

Performance at glance

Performance

1670.83 %

Latent gain

33417.41 C$

Invested capital

2000.05 C$

Annualized return

384.98 %
Build your Trading System
Automated Trading using Prorealtime ebook

Momentum strategy results on HEMOSTEMIX INC

This is the result of two momentum investment strategies applied to HEMOSTEMIX INC. The first strategy uses a momentum signal calculated on one quarter, and the second uses a momentum signal calculated on two quarters.

Momentum entry openings on HEMOSTEMIX INC

The following chart shows all the entries opened by the momentum investment system on HEMOSTEMIX INC:

HEMOSTEMIX INC momentum entries
  • The first momentum investment strategy would give 3360.89% of return on HEMOSTEMIX INC. That represents 243659.45C$ of latent gain with 7249.85C$ of employed capital.
  • The second momentum investment strategy would give 3855.85% of return on HEMOSTEMIX INC. That represents 173512.46C$ of latent gain with 4499.98C$ of employed capital.
Performance at glance (1Q Momentum)

Performance

3360.89 %

Latent gain

243659.45 C$

Invested capital

7249.85 C$

Annualized return

213.68 %
Performance at glance (2Q Momentum)

Performance

3855.85 %

Latent gain

173512.46 C$

Invested capital

4499.98 C$

Annualized return

998.92 %

Momentum equity curve on HEMOSTEMIX INC

The following chart shows the equity curve of the two momentum strategies applied to HEMOSTEMIX INC:

HEMOSTEMIX INC momentum equity

Note: the dividends potentially given by HEMOSTEMIX INC are not integrated into the calculation of the equity curve neither the performance of the strategy. The integration of the dividends will be available soon.


Employed capital on HEMOSTEMIX INC

The following chart shows the employed capital evolution of the two momentum strategies on HEMOSTEMIX INC since the beginning:

HEMOSTEMIX INC

Note: the algorithm buys for a maximum of 250$ per entry. If the stock price is greater than 250C$, the system buys only one stock per entry. The investment system stops automatically when the financial exposure reaches 10000C$.


Buy the dip strategy result on HEMOSTEMIX INC

Buy the dip entry openings on HEMOSTEMIX INC

HEMOSTEMIX INC

The performance achieved by the robo-advisor on HEMOSTEMIX INC is 500.0%. That represents 1249.93$ of latent gain with 249.99C$ of employed capital. The following chart shows HEMOSTEMIX INC stock price with all the entries opened by the automated investment system.

Note: The blue line represents the weekly stock price of HEMOSTEMIX INC, and the green triangles represent the entry openings. The artificall robo-advisor needs at least 100 weeks of trading history to work.

Performance at glance

Performance

500.0 %

Latent gain

1249.93 C$

Invested capital

249.99 C$

Annualized return

213.68 %

Equity curve of the strategy applied to HEMOSTEMIX INC

The following chart shows the result of the investment strategy applied to HEMOSTEMIX INC:

HEMOSTEMIX INC

Note: the dividends potentially given by HEMOSTEMIX INC are not integrated into the calculation of the equity curve neither the performance of the strategy. The integration of the dividends will be available soon.


Employed capital on HEMOSTEMIX INC

The following chart shows the employed capital evolution since the beginning of the investment strategy on HEMOSTEMIX INC:

HEMOSTEMIX INC

Note: the algorithm buys for a maximum of 250$ per entry. If the stock price is greater than 250$, the system buys only one stock per entry. The investment system stops automatically when the financial exposure reaches 10000$.


Investment strategies comparison on HEMOSTEMIX INC

In this section, I will compare the three previous investment strategies applied to HEMOSTEMIX INC.

Equity curve comparison on HEMOSTEMIX INC

The following chart shows the equity curve of the artificall advisor, the trend folowing and the automatic investment strategies:

HEMOSTEMIX INC investment strategy comparison

Employed capital comparison on HEMOSTEMIX INC

HEMOSTEMIX INC investment comparison

Performance comparison on HEMOSTEMIX INC

Strategy Latent Profit Growth Employed capital CAGR
Automatic investment 1670.83% 33417.41C$ 2000.05C$ 384.98%
Momentum 1 quarter 3360.89% 243659.45C$ 7249.85C$ 819.73%
Momentum 2 quarters 3855.85% 173512.46C$ 4499.98C$ 998.92%
Non-directional 500.0% 1249.93C$ 249.99C$ 213.68%
Annualized return comparison

Automatic investment

384.98 %

Momentum 1Q

998.92 %

Momentum 2Q

998.92 %

Non-directional

213.68 %

Correlated stocks

Here are the most positively and negatively correlated stocks with HEMOSTEMIX INC:

Positive correlations

Most correlated stocks this year


Most correlated stocks last 3 months

Negative correlation

Most negatively correlated stocks this year


Most negatively correlated stocks last 3 months

Note: The algorithm computes the probability of correlation between HEMOSTEMIX INC and the other stocks. There may be false positives or some missing correlated stocks. If the price of HEMOSTEMIX INC does not vary for 36 weeks, the correlation calculation result will be wrong.


Company information

Company name HEMOSTEMIX INC
Country Canada
City Calgary
Address 707-7th Avenue SW
Phone
Website www.hemostemix.com
FullTime employees
Industry Biotechnology
Sector Healthcare
Exchange XTSX
Ticker HEM.XTSX
Market www.tsx.com

HEMOSTEMIX INC ESG Scores

Environment scores

Environment ESG Factors Scores
Environment Score 0
Peer Environment Performance unknown
Environment Percentile unknown
Palm Oil unknown
Nuclear unknown
Fur Leather unknown
GMO unknown
Coal unknown
Pesticides unknown
Animal Testing unknown

Social scores

Social ESG Factors Scores
Social Score 0
Peer Social Performance unknown
Social Percentile unknown
Highest Controversy unknown
Peer Highest Controversy Performance unknown
Adult unknown
Gambling unknown
Alcoholic unknown
Tobacco unknown
Catholic unknown
Controversial Weapons unknown
Small Arms unknown
Military Contract unknown
Peer Count unknown

Related Controversy:


Governance scores

Governance ESG Factors Scores
Governance Score 0
Peer Governance Performance unknown
Governance Percentile unknown

ESG at glance
Total ESG Scores: unknown
Environment Score: 0
Social Score: 0
Governance Score: 0

ESG Performance: unknown

Peer Group: unknown

Peer Esg Score Performance: unknown

Rating Year: unknown

Rating Month: unknown

Max Age: unknown

Percentile: unknown